![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Macomics collaborates with the Institute of Oncology Research, focused on studying formulation and development through ENIGMAC macrophage drug discovery platform for the treatment of prostate cancer.
Lead Product(s): Macrophage-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Institute of Oncology Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 19, 2024
Details:
The collaboration will combine advanced human ex vivo models with new therapeutic approaches to support Macomics’ continued exploration of novel macrophage biology.
Lead Product(s): Macrophage-targeted Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: IFOM
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 13, 2024
Details:
Under the terms of the agreement, Macomics will identify and characterise antibody candidates against the novel target of interest using its ENIGMACTM macrophage drug discovery platform.
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 23, 2023
Details:
Macomics is developing precision medicines to modulate macrophages for the treatment of cancer. It is progressing a diversified portfolio of therapies targeting disease-specific tumour-associated macrophages (‘TAMs’) towards the clinic.
Lead Product(s): Macrophage-based Therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Caribou Property Limited
Deal Size: $5.8 million Upfront Cash: Undisclosed
Deal Type: Financing July 29, 2021